ScreenerHero
UTHRUnited Therapeutics Corporation
NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · unither.com
526.49USD-0.50%Mkt Cap: 22.70B $P/E: 18.95

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationa…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
ALM
Almirall, S.A.
$2.47BUSDP/E 37.4

Key Statistics

Company
Market Cap22.70B $
Enterprise Value19.68B $
Revenue (TTM)3.15B $
Gross Profit2.80B $
Net Income (TTM)1.33B $
Revenue/Share72.85 USD
Last Price526.49 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.4K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS91307C1027
Valuation
P/E (Trailing)18.95
P/E (Forward)17.35
PEG2.22
EV/EBITDA13.16
EV/Revenue6.24
P/S7.08
P/B3.47
EPS (TTM)27.46
EPS (Forward)30.03
52W Range
302.1973% of range609.35
52W High609.35 USD
52W Low302.19 USD
Profitability
Gross Margin87.92%
Oper. Margin42.23%
EBITDA Margin47.43%
Profit Margin41.94%
ROE18.81%
ROA16.94%
Growth
Revenue Growth-1.90%
Earnings Growth13.40%
Cash Flow & Leverage
Operating CF1.56B $
CapEx (TTM)526.00M $
FCF Margin17.66%
FCF Yield2.45%
Net Debt-2.66B $
Net Debt/EBITDA-1.78
Balance Sheet
Debt/Equity—
Current Ratio5.73
Quick Ratio4.89
Book Value/Sh149.97 USD
Cash/Share62.07 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split2:1
Split DateSep 23, 2009
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)664.33 USD
Upside (mean)+26.2%
Target Range515.00 USD – 725.00 USD
$515.00+26.2% to mean$725.00
# Analysts12
Ownership
Shares Out.42.89M
Float39.21M
Insiders2.00%
Institutions100.03%
Short Interest
Short Ratio5.6d
Short % Float6.32%
Short % Out.5.42%
Shares Short2.32M
Short (prev mo.)2.12M
Technical
SMA 50533.68 (-1.3%)
SMA 200520.48 (+1.2%)
Beta0.56
S&P 52W Chg18.16%
Avg Vol (30d)427.23K
Avg Vol (10d)508.83K
Technical Indicators
RSI (14)52.4
MACD-6.3896
MACD Signal-6.4974
MACD Hist.+0.1078
BB Upper541.90 USD
BB Middle521.31 USD
BB Lower500.71 USD
BB Width7.90%
ATR (14)14.92 USD
Vol Ratio (20d)0.90x